Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals aged 18 years and older who voluntarily decide to participate in this study and provide written informed consent~* Female of childbearing potential who agree to use medically allowed methods of contraception during the study period~* Individuals who agrees not to perform blood donation and transfusion during the study period~Exclusion Criteria:~* Individual being considered to be confirmed COVID-19~* Direct contact with COVID-19 infected person within 14 days prior to the 1st dose of the IP~* Individuals at high risk of exposure to SARS-CoV-2~* Individuals with clinically significant abnormalities in clinical laboratory tests, ECGs, and chest X-ray during screening~* Individuals with fever within 72 hours prior to the 1st dose of the IP or suspected other infectious disease or symptoms associated with other infectious disease~* Individuals with serious medical or psychiatric disease~* History of SARS-CoV or MERS-CoV infection~* History of allergic reaction or hypersensitivity reactions to any of components of the IP~* History of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination~* History of receiving organ or bone marrow transplant~* Suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination~* History of vaccination against SARS-CoV, MERS-CoV, or SARS-CoV-2~* History of vaccination with test vaccine substance~* Treatment with immunosuppressants or immune modifying drugs~* History of treatment with antipsychotics or opioid dependence~* Pregnant or lactating women~* Other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test group(EuCorVac-19) - Cohort A (Type: EXPERIMENTAL): Cohort A - Immunogenicity cohort
- Comparator group(ChAdOx1) - Cohort A (Type: ACTIVE_COMPARATOR): Cohort A - Immunogenicity cohort
- Test group(EuCorVac-19) - Cohort B (Type: EXPERIMENTAL): Cohort B - Safety cohort
- Comparator group(ChAdOx1) - Cohort B (Type: ACTIVE_COMPARATOR): Cohort B - Safety cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).